NCT04586062Available不适用
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
Kedrion S.p.A.0 个研究点开始时间: 2020年10月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
研究概览
简要总结
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects diagnosed with LC associated with Type I plasminogen deficiency, confirmed by laboratory documentation at screening visit, with or without ocular pseudomembranes. The presence of membranes in different areas is not an exclusion criterion.
- •Subjects and their legally authorized representative, in the case of subjects <18 years of age, should be informed of the nature of the treatment, agree to its provision, sign and date the informed and data handling consent forms approved by the IRB.
- •Subjects must be available for the duration of the treatment and agree to be compliant with the protocol visit and follow-up schedule.
- •Subjects agree to keep the treating physician or specialist in charge informed about any occurrence related to the treatment.
排除标准
- •Subjects with any condition which, in the opinion of the treating physician or specialist in charge might interfere with the treatment.
- •Females of childbearing potential who are either pregnant or not using an adequate method of birth control (adequate is defined as hormonal contraceptive or partner vasectomy for at least 3 months, condoms, intrauterine device [IUD], abstinence or other prescribed birth control). Enrolled males must agree to utilize appropriate contraceptive methods to prevent pregnancy in partners.
- •Females who are breastfeeding.
研究者
相似试验
Available
不适用
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCANCT06034886Biohaven Pharmaceuticals, Inc.
已完成
3 期
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment AlternativesDepressionNCT04476446Janssen-Cilag, S.A.41
Unknown
不适用
Intermediate-Sized Expanded Access StudyAmyotrophic Lateral SclerosisNCT05597436Seelos Therapeutics, Inc.
Approved For Marketing
不适用
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)Bardet-Biedl Syndrome (BBS)ObesityNCT05183802Rhythm Pharmaceuticals, Inc.
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.